Home > Journals > Chirurgia > Past Issues > Chirurgia 2002 February;15(1) > Chirurgia 2002 February;15(1):25-30

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Chirurgia 2002 February;15(1):25-30

Copyright © 2002 EDIZIONI MINERVA MEDICA

language: Italian

Recent advances for thromboembolic disease prophylaxis and treatment in general surgery

Bertolaccini L., Canino V.


PDF


Coagulative cascade is made by a series of enzymatic reactions that lead to sequential activation of coagulative factors. Venous thromboses are principally due to an alteration of the coagulative cascade caused by blood stasis. Without treatment, thrombus develops causing deep venous thrombosis. Thromboembolic disease is a frequent complication in surgical patients, cancer patients, chronic diseases, or in in-bed patients. In most cases, thromboembolic pathology is clinically silent. Antithrombotic prophylaxis is routinely used in medical or surgical patients according to their risk level. The most used pharmacological agents include unfractionated heparin, oral anticoagulant, and low molecular weight heparins. Recently a new drug, the pentasaccharide Fondaparinux, has been synthesized. Pentasaccharide is in a new class of antithrombotic agents, the factor Xa selective inhibitors, which bind the principal endogenous coagulative cascade inhibitor, the protein antithrombin. Despite these considerations, the incidence of thromboembolic pathology is still high and this demonstrates the demand of new antithrombotic therapies. The ideal antithrombotic drug should have a better cost-beneficial ratio and a reduced bleeding risk.

top of page